Technology

SSI Platform

ProteoCell is currently developing a unique and proprietary platform for the expression of recombinant biopharmaceutical drug products rapidly, efficiently, and in a regulatory compliant manner. By combining cell line development with bioprocess development, ProteoCell is able to screen the best, most stable, and most productive recombinant clone with the optimal bioprocess to produce it. ProteoCell’s targets for this platform include yield targets of >1g/L for full antibodies in the Master Cell Banks, and is presently shooting for targets >2-3g/L in optimized bioprocess systems for full antibody molecules.

Who is SSI for?
Companies looking to use next generation expression systems for highly productive, stably produced recombinant proteins at a low cost. Small and medium size biotech and biopharma companies looking for a production platform with scalability—but without heavy royalty commitments present on the market today. Companies with larger and more complex recombinant proteins that are not stably expressed using traditional expression systems.